A recent article in Health Affairs considers how secondary patenting can extend market exclusivity and delay generic competition. Amin and Kesselheim examine two key anti-HIV drugs Norvir and Kaletra. Through the analysis of 108 patents, they find generic competition could be delayed for an additional twelve years beyond the expiration of the patents on the … Continue reading Guest column : Is “evergreening” of drug patents all bad?
Apothecurry 